[A comparative clinical study of modified IA "3+4" regimen and intermediate-dose cytarabine regimen in the consolidation treatment of low-risk acute myeloid leukemia]

Zhonghua Xue Ye Xue Za Zhi. 2022 Jul 14;43(7):594-597. doi: 10.3760/cma.j.issn.0253-2727.2022.07.011.

[Article in Chinese]

Authors

X H Liu¹, J S Jia¹, J Wang¹, L Z Gong¹, F F Tang¹, W J Yu¹, X L Zhu¹, Y Wang¹, Q Jiang¹, Y J Chang¹, X S Zhao¹, G R Ruan¹, Y Z Qin¹, X J Huang¹, H Jiang¹

Affiliation

¹ Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.

PMID: 36709138
PMCID: PMC9395562
DOI: 10.3760/cma.j.issn.0253-2727.2022.07.011

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cytarabine* / therapeutic use
Humans
Idarubicin
Leukemia, Myeloid, Acute* / drug therapy
Remission Induction

Substances

Cytarabine
Idarubicin

Grants and funding

基金项目：首都临床特色应用研究基金（Z181100001718126）